{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Geisler A"],"funding":["Deutsche Forschungsgemeinschaft","IBB Business Team GmbH program ProValid"],"pagination":["11224"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11508574"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["25(20)"],"pubmed_abstract":["Pancreatic cancer is one of the deadliest cancers globally, with limited success from existing therapies, including chemotherapies and immunotherapies like checkpoint inhibitors for patients with advanced pancreatic ductal adenocarcinoma (PDAC). A promising new approach is the use of oncolytic viruses (OV), a form of immunotherapy that has been demonstrated clinical effectiveness in various cancers. Here we investigated the potential of the oncolytic coxsackievirus B3 strain (CVB3) PD-H as a new treatment for pancreatic cancer. In vitro, PD-H exhibited robust replication, as measured by plaque assays, and potent lytic activity, as assessed by XTT assays, in most pancreatic tumor cell lines, outperforming two other coxsackievirus strains tested, H3N-375/1TS and CVA21. Thus, H3N-375/1TS show"],"journal":["International journal of molecular sciences"],"pubmed_title":["Oncolytic Coxsackievirus B3 Strain PD-H Is Effective Against a Broad Spectrum of Pancreatic Cancer Cell Lines and Induces a Growth Delay in Pancreatic KPC Cell Tumors In Vivo."],"pmcid":["PMC11508574"],"funding_grant_id":["536819681","VAL121/2023"],"pubmed_authors":["Fechner H","Elsner L","Klopfleisch R","Geisler A","Dieringer B","Kurreck J"],"additional_accession":[]},"is_claimable":false,"name":"Oncolytic Coxsackievirus B3 Strain PD-H Is Effective Against a Broad Spectrum of Pancreatic Cancer Cell Lines and Induces a Growth Delay in Pancreatic KPC Cell Tumors In Vivo.","description":"Pancreatic cancer is one of the deadliest cancers globally, with limited success from existing therapies, including chemotherapies and immunotherapies like checkpoint inhibitors for patients with advanced pancreatic ductal adenocarcinoma (PDAC). A promising new approach is the use of oncolytic viruses (OV), a form of immunotherapy that has been demonstrated clinical effectiveness in various cancers. Here we investigated the potential of the oncolytic coxsackievirus B3 strain (CVB3) PD-H as a new treatment for pancreatic cancer. In vitro, PD-H exhibited robust replication, as measured by plaque assays, and potent lytic activity, as assessed by XTT assays, in most pancreatic tumor cell lines, outperforming two other coxsackievirus strains tested, H3N-375/1TS and CVA21. Thus, H3N-375/1TS show","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Oct","modification":"2025-04-18T14:58:17.19Z","creation":"2025-04-07T01:20:34.659Z"},"accession":"S-EPMC11508574","cross_references":{"pubmed":["39457005"],"doi":["10.3390/ijms252011224"]}}